SLC19A3 (NM_025243) Human Untagged Clone
$457.00
In Stock*
Specifications
| Product Data | |
| Type | Human Untagged Clone |
|---|---|
| Target Symbol | SLC19A3 |
| Synonyms | BBGD; THMD2; thTr-2; THTR2 |
| Vector | pCMV6-XL4 |
| E. coli Selection | Ampicillin (100 ug/mL) |
| Mammalian Cell Selection | None |
| Sequence Data | |
| Restriction Sites | ECoRI-NOT | |
| ACCN | NM_025243 |
| Insert Size | 4000 bp |
| OTI Disclaimer | Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g., by representing an alternative RNA splicing form or single nucleotide polymorphism (SNP). |
| Components | The ORF clone is ion-exchange column purified and shipped in a 2D barcoded Matrix tube containing 10ug of transfection-ready, dried plasmid DNA (reconstitute with 100 ul of water). |
| Reconstitution Method | 1. Centrifuge at 5,000xg for 5min. 2. Carefully open the tube and add 100ul of sterile water to dissolve the DNA. 3. Close the tube and incubate for 10 minutes at room temperature. 4. Briefly vortex the tube and then do a quick spin (less than 5000xg) to concentrate the liquid at the bottom. 5. Store the suspended plasmid at -20°C. The DNA is stable for at least one year from date of shipping when stored at -20°C. |
| Note | Plasmids are not sterile. For experiments where strict sterility is required, filtration with 0.22um filter is required. |
| Shipping | Ambient |
| Reference Data | |
| RefSeq | NM_025243.2, NP_079519.1 |
| RefSeq Size | 3532 bp |
| RefSeq ORF | 1491 bp |
| Locus ID | 80704 |
| UniProt ID | Q9BZV2 |
| Cytogenetics | 2q36.3 |
| Domains | Folate_carrier |
| Protein Families | Transmembrane |
| Summary | This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild cognitive disability, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.provided by RefSeq, Jan 2010 |
Reviews
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
"NM_025243" in other vectors (5)
| SKU | Description | Size | Price | |
|---|---|---|---|---|
| RC206409 | SLC19A3 (Myc-DDK-tagged)-Human solute carrier family 19, member 3 (SLC19A3) | 10 ug |
$457.00
|
|
| RC206409L3 | Lenti ORF clone of Human solute carrier family 19, member 3 (SLC19A3), Myc-DDK-tagged | 10 ug |
$757.00
|
|
| RC206409L4 | Lenti ORF clone of Human solute carrier family 19, member 3 (SLC19A3), mGFP tagged | 10 ug |
$757.00
|
|
| RG206409 | SLC19A3 (tGFP-tagged) - Human solute carrier family 19, member 3 (SLC19A3) | 10 ug |
$489.00
$657.00
|
|
| SC324186 | SLC19A3 (untagged)-Human solute carrier family 19, member 3 (SLC19A3) | 10 ug |
$457.00
|
|
Citations
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
